Yusheng. you, Thank
financials. latest I will with our supplement remarks Yusheng's and numbers
the composition So see of terms metrics And starting over first a can on the in make migrated Page model X years, in-hospital you model, have increasingly model; to XXXX. dominant test in an our is from volumes. channel our central our lab we in-hospital operating share
of volume growth very XX%. achieved grew in-hospital terms about our half grew volume volume in a We year-over-year in second overall, On year-over-year. the good XXXX. have XX% basis, our And
you more institutionalized volumes in-hospital model. and see profitable competitively managed here, is have down As less lab the our irregular central as a more or in that can we compared intensive channel to
So we're transition. happy about the results of and progress our
As see overall XX% our numbers, you can in growth. QX
strong reflecting, transition two things, good share the think, very not in-hospital, also only a number, incumbents but from towards other gain I think I a in that's market.
of You base in was a the might because last year Shanghai. lockdown that say COVID low QX
we Look strong. grew grew very on basis. sequential overall graph on In-hospital also on at a here XX% the a XX% sequential and volumes a have sequential basis, basis grown
quarter. are end latest progress since see reports that volumes can July. happy health heading China's QX. the second news testing very on industry-wide the about of still results numbers, So in we stable is Then of we into in-hospital our There and disturbance based industry care are during our
of we channel resilience So that about lab the more very channel. Central is vulnerable. are happy
that has towards increased in-hospital So channel QX. shift seen the in
better ahead current have we So benefiting industry and the from way we're channel turbulence. in-hospital happy the time, of we're that towards positioned
volume X. on overall Page that's trend the So
financial numbers. Then X, to going Page our
is non-GAAP and share-based excluding the news out this amortization. expenses, on breakeven, depreciation item excluding mentioned, biggest Yusheng of quarter As i.e., a compensation, and R&D and basis,
So that achieved business, and our progress. first the have we're we happy that is proud of commercial and breakeven quarter of
be continue And the have in the in very the if efficient. at of and expenses XXs We of here, second you QX, that look reorganization last our as we've is our gone half revenue start of XX% to about the marketing at were sales range out the at of XXXX, and a carried percent result into breakdown year. that sales force and low we
bearing and very we're lid of fruits Then expenses continue going forward. a marketing sales that on effort. tight keep we'll the to So
In expenses addition to that, down. you also can that have trended our also see G&A
our So results importantly, got we collections have And overhead customers. of we or hospital receivable been in more efficiently. have have managing our we from better increased terms
is year. quarter credit in carried which the there provision in line a the in So second this loss, drop of the is G&A
G&A well. helped has that as expenses us So lower
have and down expenses our So very still we're overall, trend you continued can well. see the managing expenses to operating
the result. So overall that's
One more segment. highlight is thing pharma to our
And achieved if this in good leading that So look this grown grew by we've half segment. about you of the quarter, that a if we first XX%. indicator, look revenue the during the of at metric our you growth by contract year, at signed have We value XX%.
execute So converted pharma revenue. we they sign more into continue get as contracts, to on build these And backlog. projects, we our
excluding that this we gross contributed a gross margin, revenue i.e., very well the profit on And grown overall year results So basis, non-GAAP achieved XX% by our growth our we've basis. good over in has XX% also about a depreciation. around year-over-year have on past. Then
our X the breakeven expenses lower on That's and and in growth continued overall, time first Page for history. operating the So numbers financial
this laid out this X, and to on executing at is Page of we've We've cash on our balance. moving year, start which the Now been track.
schedule. -- to still executed few clinical on our on according mentioned, early and time development, we as and large still are we detection a Yusheng So well programs have product multi-cancer these
our we So again, to -- cash according our outflow plan. is,
year, this So RMB about for outflow XXX of we've plan we about XXX of in first and this the million million RMB year. half had
on that's So track. progressing
the finish programs will on our We this year development of MCED most of by clinical end
laid R&D of run programs. expenses year. out this expect same we complete number down the program lower our as expense. clinical will at the start So as is Then this we And naturally those we
XXX million RMB that operating next any upside year, So we from commercial and that achieve excludes business. the may outflow
three capitalized burn our balance. share reduced in terms for and the of next cash years So well
So we'll our questions. this prepared and we see if remarks, concludes have
